|
Post by peppy on Jan 8, 2019 16:58:32 GMT -5
Taking the quote in context, Rothblatt was talking about 400M+ total split over FIVE different products: BEAT, INCREASE, PERFECT, Technosphere, and SPIRESTA. So Mannkind will be getting much less than that $48 million per year (everything else in your, or mango's, set of assumptions held constant).
I'll have to listen again when I get a chance because that is not how I heard it. I believe the $400M is the current annual net sales of Tyvaso. Rothblatt stated that the hope is the 5 products will generate $1 billion+ down the line. If it works out, the Technosphere platform would replace the current Tyvaso nebulizer AND be the delivery platform for the Increase, Perfect and the inhaled component of the Beat product. Spiresta is described as a complimentary product to Treprostinil Technosphere to serve as an as needed product in between regular treatments.
So it sounded to me like the Technosphere product has a possibility to replace the current $400M and be a significant component of the first 3 products in trial (BEAT, INCREASE, and PERFECT). How much of the $1 billion projection is coming from Spiresta I couldn't tell, but Technosphere's portion seemed to be in the majority.
|
|
|
Post by Clement on Jan 8, 2019 16:58:36 GMT -5
|
|
|
Post by peppy on Jan 8, 2019 17:00:35 GMT -5
I'll have to listen again when I get a chance because that is not how I heard it. I believe the $400M is the current annual net sales of Tyvaso. Rothblatt stated that the hope is the 5 products will generate $1 billion+ down the line. If it works out, the Technosphere platform would replace the current Tyvaso nebulizer AND be the delivery platform for the Increase, Perfect and the inhaled component of the Beat product. Spiresta is described as a complimentary product to Treprostinil Technosphere to serve as an as needed product in between regular treatments.
So it sounded to me like the Technosphere product has a possibility to replace the current $400M and be a significant component of the first 3 products in trial (BEAT, INCREASE, and PERFECT). How much of the $1 billion projection is coming from Spiresta I couldn't tell, but Technosphere's portion seemed to be in the majority.
I relistened to the relevant portions myself. Yes, 400M+ is the current net sales of Tyvaso. The call said the 5 products I listed would grow that $400M to $1 billion and more. But it's not clear to me how much of that will go to Technosphere, it wasn't said. LATER in the call, it is suggested that Ralinepag could add yet ANOTHER $1 billion in revenues to the top-line.
www.arenapharm.com/wp-content/uploads/2016/12/Ralinepag-An-Orally-Active-Prostacyclin-Receptor-Agonist-for-the-Treatment-of-Pulmonary-Arterial-Hypertension-J-Med-Chem-2017.pdf
|
|
|
Post by peppy on Jan 8, 2019 17:05:42 GMT -5
|
|
|
Post by mango on Jan 8, 2019 17:18:02 GMT -5
So Technosphere Treprostinil has the potential to net over 400M...possibly in the ~mid 2020's
Sweet
How much of that would MannKind get?
|
|
|
Post by mannmade on Jan 8, 2019 17:44:31 GMT -5
Low double digit royalty was stated but not specific so am guessing 10% to 15%.
|
|
|
Post by mango on Jan 8, 2019 17:48:22 GMT -5
Low double digit royalty was stated but not specific so am guessing 10% to 15%. 10% = 40M 15% = 60M
|
|
|
Post by mannmade on Jan 8, 2019 18:53:35 GMT -5
Low double digit royalty was stated but not specific so am guessing 10% to 15%. 10% = 40M 15% = 60M exactly!
|
|
|
Post by travis1953 on Jan 8, 2019 19:15:52 GMT -5
Rothblatt explained that Spiresta is for rescue (and is not the replacement for Tyvaso nebulizer). Treprostinil Technospere is being developed to replace the Tyvaso Nebulizer. Tyvaso net sales in Q3 2018 was $108 million. What does it mean "for rescue"?
|
|
|
Post by mytakeonit on Jan 8, 2019 19:23:15 GMT -5
I guess UTHR investors are not of the day trader mentality ... After hearing what they said about technospere I would have been all over MNKD shares this morning.
Wow, what a difference a day makes.
|
|
|
Post by mango on Jan 8, 2019 19:53:17 GMT -5
Rothblatt explained that Spiresta is for rescue (and is not the replacement for Tyvaso nebulizer). Treprostinil Technospere is being developed to replace the Tyvaso Nebulizer. Tyvaso net sales in Q3 2018 was $108 million. What does it mean "for rescue"? To have as a backup, and to use as needed
|
|
|
Post by mannmade on Jan 8, 2019 20:10:23 GMT -5
Think about the below...
An Irish physician named Francis Rynd invented the hollow needle and used it to make the first recorded subcutaneous injections in 1844. Then shortly thereafter in 1853 Charles Pravaz and Alexander Wood developed a medical hypodermic syringe with a needle fine enough to pierce the skin.
That’s how long syringes have been around, over 165 years. No wonder Dr. K called them barbaric. TS has only been around about 15 years without much exposure. Wait until Uthr gets a couple of products to market, followed by RLS, Novartis, etc...
|
|
|
Post by peppy on Jan 8, 2019 20:15:16 GMT -5
Rothblatt explained that Spiresta is for rescue (and is not the replacement for Tyvaso nebulizer). Treprostinil Technospere is being developed to replace the Tyvaso Nebulizer. Tyvaso net sales in Q3 2018 was $108 million. What does it mean "for rescue"? The rescue, from respiratory arrest. They can't get oxygen into their blood. The heart a muscle, requires oxygen and glucose to beat. In the presence of oxygen one glucose molecule makes 32 ATP. fact check, 32 correct? aerobic metabolism in the presence of no oxygen one glucose molecule makes 2 ATP. fact check, 2 correct? anerobic metabolism ATP powers the cells, the heart, the pump.
|
|
|
Post by brotherm1 on Jan 8, 2019 20:17:37 GMT -5
Anyone know if in UTHR’s call Ralinepag was mentioned and how it would be used? Where will ARNA’s Ralinepag that UTHR paid 800M for shortly after their deal with MNKD for Treprostinil will fit in? It is also used to treat pulmonary hypertension. I am spot listening to the call now. Yes, it was mentioned and included in the slides. There, ARNA’s Ralinepag is described as "Potential 'Best-in-Class' Asset for PAH." And that it targets the same 'PH Who Group 1' as Treprostinil Technosphere. Slides are here, but you may have to sign up first: jpmorgan.metameetings.net/events/healthcare19/sessions/23947-united-therapeutics-corp/webcastIn attempting to understand the difference between Treprostinil and Ralinepag, can anyone decipher what this all means: Ralinepag Potent IP Receptor Agonist PAH – Time to Clinical Events Ph3 Initiated PAH – Exercise Capacity (CPET) Ph3 PAH – Exercise Capacity (6MW) Ph3 PAH – Differentiation 1H:19 Initiatio www.arenapharm.com/pipeline/#
|
|
|
Post by peppy on Jan 8, 2019 20:25:07 GMT -5
In attempting to understand the difference between Treprostinil and Ralinepag, can anyone decipher what this all means: Ralinepag Potent IP Receptor Agonist PAH – Time to Clinical Events Ph3 Initiated PAH – Exercise Capacity (CPET) Ph3 PAH – Exercise Capacity (6MW) Ph3 PAH – Differentiation 1H:19 Initiatio www.arenapharm.com/pipeline/#this schematic lends insight there. 40 meters is 131 feet.
|
|